The Italian Competition Authority (AGCM) and the Italian Medicines Agency (AIFA) recently signed a Memorandum of Understanding with a view to strengthening their cooperation. The Memorandum underlines that the two agencies share common interests, which relate in particular to keeping high levels of competition, granting access to medicines and preserving the economical balance of
The Aspen case. Anti-competitive behaviour in price negotiations with AIFA.
The South African group Aspen Pharma was fined Euro 5.2 million two weeks ago by the Italian Competition Authority (“ICA”) for having imposed excessive prices for its antitumor drugs “Cosmos” acquired from GlaksoSmithKline in 2009.
This is the third (controversial) case in which the ICA deals with allegations of anticompetitive behaviour in the pharmaceutical sector. Continue Reading The Aspen case. Anti-competitive behaviour in price negotiations with AIFA.